Medication info
Calci-O Soft Capsule 0.25 Microgram (Calcitriol)

Calci-O Soft Capsule 0.25 Microgram (Calcitriol)

Prescription medicationSoft capsuleOral
Ingredient · strength
Calcitriol›0.25μg / 1 capsule
Manufacturer / importer
Hanmi Pharmaceutical Co., Ltd.
Appearance
It is a soft capsule with a pale yellow-orange color containing a transparent yellowish white emulsion.
Packaging
30 capsules/bottle, 300 capsules/bottle
Approval status
Active

MFDS item code 199602290 · Notified 1996.03.12 · Insurance code 643502430

Summary

Main use
Treatment of renal osteodystrophy, parathyroid dysfunction, and bone disorders (e.g., rickets and osteoporosis)
Who takes it
Adults · Children
Adult dose
The optimal daily dose of this drug should be carefully determined for each patient based on serum calcium levels. Start treatment at the lowest possible dose, and do not increase the dose without close monitoring of serum calcium. ○ Patients before the dialysis stage: The initial recommended dose for adults is 0.25 ㎍ of calcitriol per day; if necessary, it may be increased to 0.5 ㎍ per day. ○ Renal osteodystrophy (patients on dialysis): The initial daily dose is 0.25 ㎍ of this drug. For patients whose serum calcium level is within the normal range or slightly low, administer 0.25 ㎍ every other day. If an adequate response in biochemical test results and clinical symptoms is not achieved, increase the dose by 0.25 ㎍ per day at intervals of 2 ~ 4 weeks. During this period, measure serum calcium at least twice weekly. Most patients respond to doses of 0.5 ~ 1.0 ㎍ per day. Since this drug improves calcium absorption from the gastrointestinal tract, some patients receiving it may be maintained on a lower calcium intake. In patients prone to hypercalcemia, a small amount of calcium may be sufficient, or calcium supplementation may not be needed at all. ○ Osteoporosis: Administer 0.25 ㎍ of this drug twice daily. During the dose stabilization period, measure serum calcium at least twice weekly. If hypercalcemia is observed, discontinue treatment until serum calcium returns to normal. Since this drug increases calcium absorption in postmenopausal patients with osteoporosis, calcium supplementation may not be necessary. ○ Hypoparathyroidism and rickets/osteomalacia: The recommended initial dose is 0.25 ㎍ of this drug each morning. If an adequate response in biochemical test results and clinical symptoms is not achieved, increase the dose at intervals of 2 ~ 4 weeks. During dose determination, measure serum calcium at least twice weekly. Malabsorption sometimes occurs in patients with hypoparathyroidism, so a higher dose may be required. ○ General: Once the optimal dose of this drug has been determined, measure serum calcium once monthly. Blood samples for serum calcium measurement should be collected without a tourniquet. If serum calcium rises by 1 mg/dL (250 μmol/L) above the normal range of 9 ~ 11 mg/dL (2,250 ~ 2,750 μmol/L), or serum creatinine rises to 120 μmol/L or higher, promptly reduce the dose sufficiently or discontinue treatment until serum calcium returns to normal. Discontinuing additional calcium supplementation is also effective for rapidly normalizing serum calcium. Carefully consider reducing dietary calcium intake as well. During hypercalcemia, measure serum calcium and phosphorus daily. Once levels return to normal, resume treatment at a dose 0.25 ㎍ per day lower than the previous dose.
Child dose
Children 36 months of age and older: 0.25 ㎍ of calcitriol per day; if necessary, the dose may be increased to 0.5 ㎍ per day. Children under 36 months of age: 10 ~ 15 ng/kg per day.

Ingredients

Manufacturer
Hanmi Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of renal osteodystrophy, parathyroid dysfunction, and bone disorders (e.g., rickets and osteoporosis)

  • Chronic renal failure
  • secondary hyperparathyroidism
  • metabolic bone disease
  • renal osteodystrophy
  • hypoparathyroidism
  • rickets
  • osteomalacia
  • osteoporosis
View approved original text

This drug is used to treat secondary hyperparathyroidism and associated metabolic bone disease in patients with chronic renal failure prior to dialysis treatment. It also helps improve renal osteodystrophy in patients undergoing hemodialysis. It is used for the treatment of hypoparathyroidism, including postoperative and idiopathic or pseudohypoparathyroidism. Additionally, it is effective for vitamin D-dependent rickets and hypophosphatemic vitamin D-resistant rickets. Lastly, it is utilized for the treatment of osteoporosis to enhance bone health. This medication is primarily used to improve kidney and bone-related disorders.

How to take

Adult dose

The optimal daily dose of this drug should be carefully determined for each patient based on serum calcium levels. Start treatment at the lowest possible dose, and do not increase the dose without close monitoring of serum calcium. ○ Patients before the dialysis stage: The initial recommended dose for adults is 0.25 ㎍ of calcitriol per day; if necessary, it may be increased to 0.5 ㎍ per day. ○ Renal osteodystrophy (patients on dialysis): The initial daily dose is 0.25 ㎍ of this drug. For patients whose serum calcium level is within the normal range or slightly low, administer 0.25 ㎍ every other day. If an adequate response in biochemical test results and clinical symptoms is not achieved, increase the dose by 0.25 ㎍ per day at intervals of 2 ~ 4 weeks. During this period, measure serum calcium at least twice weekly. Most patients respond to doses of 0.5 ~ 1.0 ㎍ per day. Since this drug improves calcium absorption from the gastrointestinal tract, some patients receiving it may be maintained on a lower calcium intake. In patients prone to hypercalcemia, a small amount of calcium may be sufficient, or calcium supplementation may not be needed at all. ○ Osteoporosis: Administer 0.25 ㎍ of this drug twice daily. During the dose stabilization period, measure serum calcium at least twice weekly. If hypercalcemia is observed, discontinue treatment until serum calcium returns to normal. Since this drug increases calcium absorption in postmenopausal patients with osteoporosis, calcium supplementation may not be necessary. ○ Hypoparathyroidism and rickets/osteomalacia: The recommended initial dose is 0.25 ㎍ of this drug each morning. If an adequate response in biochemical test results and clinical symptoms is not achieved, increase the dose at intervals of 2 ~ 4 weeks. During dose determination, measure serum calcium at least twice weekly. Malabsorption sometimes occurs in patients with hypoparathyroidism, so a higher dose may be required. ○ General: Once the optimal dose of this drug has been determined, measure serum calcium once monthly. Blood samples for serum calcium measurement should be collected without a tourniquet. If serum calcium rises by 1 mg/dL (250 μmol/L) above the normal range of 9 ~ 11 mg/dL (2,250 ~ 2,750 μmol/L), or serum creatinine rises to 120 μmol/L or higher, promptly reduce the dose sufficiently or discontinue treatment until serum calcium returns to normal. Discontinuing additional calcium supplementation is also effective for rapidly normalizing serum calcium. Carefully consider reducing dietary calcium intake as well. During hypercalcemia, measure serum calcium and phosphorus daily. Once levels return to normal, resume treatment at a dose 0.25 ㎍ per day lower than the previous dose.

Child dose

Children 36 months of age and older: 0.25 ㎍ of calcitriol per day; if necessary, the dose may be increased to 0.5 ㎍ per day. Children under 36 months of age: 10 ~ 15 ng/kg per day.

Precautions

This drug should not be used in patients with diseases related to hypercalcemia. Patients with calcium stones or hypercalciuria should also avoid administration. People allergic to this drug or similar class medications should not take it. Patients with symptoms from vitamin D overdose or those with primary hyperparathyroidism should not use this drug. Women who are pregnant or may become pregnant, nursing mothers, children, patients with a history of kidney stones, and those with sarcoidosis should use it cautiously. This drug is an active metabolite of vitamin D, and if taken in excess, can cause hypercalcemia and calcium toxicity symptoms, so the recommended dosage should be strictly adhered to. During treatment, serum calcium levels should be regularly monitored to maintain normal ranges by adjusting the dosage. In case of overdose, symptoms like nausea, vomiting, constipation, headache, anxiety, palpitations, and other effects may occur; immediate consultation with healthcare professionals is necessary. Calcium intake should also be properly regulated, ensuring not to exceed recommended levels. This drug may increase the risk of hypercalcemia if taken with other vitamin D preparations or calcium supplements, so caution should be exercised during co-administration. Particularly, interactions can occur with diuretics, digitalis, corticosteroids, so you must inform your physician about all medications being taken. In cases of pregnancy or breastfeeding, if this drug is required, it must be administered cautiously under the physician's judgement, monitoring both maternal and infant serum calcium levels. In children and the elderly, body functions may vary, hence the dosage should be carefully determined and monitored regularly. In case of overdose, you should stop taking the medication immediately and seek appropriate treatment at a medical institution, and hospitalization may be necessary for severe hypercalcemia symptoms. This drug should be stored in a cool place below 25 degrees Celsius, avoiding light and moisture, and kept out of reach of children. It should be stored in its original container to prevent quality degradation or misuse.

Side effects

  • Nausea
  • diarrhea
  • loss of appetite
  • constipation
  • vomiting
  • gastric discomfort
  • abdominal pain
  • thirst
  • abdominal cramps
  • hypokinetic ileus
Show 92 more
  • stomach pain
  • abdominal discomfort
  • epigastric pain
  • abdominal bloating
  • stomatitis
  • thirst and dry mouth
  • pancreatitis
  • metallic taste
  • restlessness
  • anxiety
  • insomnia
  • headache
  • apathy
  • drowsiness
  • psychosis
  • depression
  • coma
  • palpitations
  • deep vein thrombosis
  • hypertension
  • sensory abnormalities
  • calcification around the joints
  • bone pain
  • runny nose
  • epistaxis
  • urinary tract infection
  • urinary stones
  • AST elevation
  • ALT elevation
  • LDH elevation
  • BUN elevation
  • creatinine elevation
  • increased serum uric acid
  • nephrocalcinosis
  • kidney stones
  • itching
  • hives
  • rash
  • dry skin
  • conjunctivitis
  • conjunctival hyperemia
  • photophobia
  • weakness
  • limb pain
  • polyuria
  • nocturia
  • dehydration
  • ALP elevation
  • hypermagnesemia
  • hypercalciuria
  • hyperphosphatemia
  • increased lymphocytes
  • increased hematocrit
  • increased neutrophils
  • increased hemoglobin
  • fatigue
  • abdominal pain
  • feeling of heat
  • fever associated with thirst
  • chest pain
  • menstrual disorders
  • facial flushing
  • low back pain
  • pain in lower limbs
  • coldness of the extremities
  • edema
  • metastatic calcification
  • myasthenia
  • nutritional disorders
  • weight loss
  • high fever
  • myalgia
  • proteinuria
  • growth retardation
  • cortical calcification of the kidney
  • myocardial calcification
  • pulmonary calcification
  • pancreatic parenchymal calcification
  • hypercholesterolemia
  • decreased libido
  • loss of appetite
  • headache
  • vomiting
  • constipation
  • atrophic degeneration
  • sensory disorders
  • fever accompanied by thirst
  • polyuria
  • dehydration
  • lethargy
  • growth suppression
  • urinary tract infection

Not everyone experiences these, and they can vary from person to person.

Storage

This drug should be stored in a sealed container to prevent air ingress, preferably at room temperature between 1 to 30 degrees Celsius. By doing so, the drug's efficacy can be well maintained.

Appearance and packaging

Appearance

It is a soft capsule with a pale yellow-orange color containing a transparent yellowish white emulsion.

Package unit

30 capsules/bottle, 300 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.